Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1944 1
1958 1
1961 1
1966 2
1968 3
1969 1
1970 1
1971 1
1972 1
1973 2
1975 2
1977 1
1978 4
1979 1
1983 2
1984 1
1985 1
1987 1
1989 4
1990 6
1991 4
1992 10
1993 7
1994 3
1995 2
1996 6
1997 6
1998 8
1999 10
2000 16
2001 35
2002 32
2003 44
2004 45
2005 52
2006 51
2007 48
2008 55
2009 45
2010 51
2011 35
2012 32
2013 40
2014 45
2015 45
2016 52
2017 48
2018 49
2019 67
2020 75
2021 80
2022 60
2023 49
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

1,173 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Baez-Schon
Page 1
Titin mutations and muscle disease.
Kellermayer D, Smith JE 3rd, Granzier H. Kellermayer D, et al. Pflugers Arch. 2019 May;471(5):673-682. doi: 10.1007/s00424-019-02272-5. Epub 2019 Mar 27. Pflugers Arch. 2019. PMID: 30919088 Free PMC article. Review.
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
Saber H, Del Valle P, Ricks TK, Leighton JK. Saber H, et al. Regul Toxicol Pharmacol. 2017 Nov;90:144-152. doi: 10.1016/j.yrtph.2017.09.001. Epub 2017 Sep 5. Regul Toxicol Pharmacol. 2017. PMID: 28887049 Review.
We also collected information on the design of dose-finding clinical trials. Sponsors have used different MABEL approaches for FIH dose selection. To better assess acceptable approaches, FIH doses were computed from nonclinical studies and compared to the maximum tolerated …
We also collected information on the design of dose-finding clinical trials. Sponsors have used different MABEL approaches for FIH do …
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
Muller PY, Milton M, Lloyd P, Sims J, Brennan FR. Muller PY, et al. Curr Opin Biotechnol. 2009 Dec;20(6):722-9. doi: 10.1016/j.copbio.2009.10.013. Epub 2009 Nov 5. Curr Opin Biotechnol. 2009. PMID: 19896825 Review.
These investigations provide the essential information required for the selection of a safe starting dose and escalation for FIH trials based on toxicology and pharmacology data and the minimal anticipated biological effect level (MABEL) by integrating all available in viv …
These investigations provide the essential information required for the selection of a safe starting dose and escalation for FIH trials base …
Transitions.
Antin PB. Antin PB. Dev Dyn. 2017 Dec;246(12):969. doi: 10.1002/dvdy.24602. Dev Dyn. 2017. PMID: 29144604 Free article. No abstract available.
Deconstructing 'Mabel'.
Law S, Muir F. Law S, et al. Educ Prim Care. 2016 Jul;27(4):322-4. doi: 10.1080/14739879.2016.1168619. Epub 2016 Apr 5. Educ Prim Care. 2016. PMID: 27046652 No abstract available.
Nebulin, a multi-functional giant.
Chu M, Gregorio CC, Pappas CT. Chu M, et al. J Exp Biol. 2016 Jan;219(Pt 2):146-52. doi: 10.1242/jeb.126383. J Exp Biol. 2016. PMID: 26792324 Free PMC article. Review.
1,173 results